AR089182A1 - AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF LRRK2 - Google Patents
AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF LRRK2Info
- Publication number
- AR089182A1 AR089182A1 ARP120104438A ARP120104438A AR089182A1 AR 089182 A1 AR089182 A1 AR 089182A1 AR P120104438 A ARP120104438 A AR P120104438A AR P120104438 A ARP120104438 A AR P120104438A AR 089182 A1 AR089182 A1 AR 089182A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- optionally substituted
- halogen
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Los compuestos son útiles para el tratamiento de enfermedades asociadas con el receptor de la LRRK2, por ejemplo la enfermedad de Parkinson. Reivindicación 1: Compuestos de la fórmula (1) o sales farmacéuticamente aceptables de los mismos, en la que: m es un número de 0 a 3; X es: -NRᵃ-; -O-; o -S(O)ʳ-, en el que r es un número de 0 a 2 y Rᵃ es hidrógeno o alquilo C₁₋₆; R¹ es: alquilo C₁₋₆; alquenilo C₂₋₆; alquinilo C₂₋₆; haloalquilo C₁₋₆; (alcoxi C₁₋₆)-alquilo C₁₋₆; hidroxi-alquilo C₁₋₆; amino-alquilo C₁₋₆; (alquilsulfonil C₁₋₆)-alquilo C₁₋₆; cicloalquilo C₃₋₆ opcionalmente sustituido por alquilo C₁₋₆ o halógeno; (cicloalquil C₃₋₆)-alquilo C₁₋₆, cuya porción cicloalquilo C₃₋₆ está opcionalmente sustituida por alquilo C₁₋₆; tetrahidropiranilo; tetrahidrofuranilo; tetrahidrofuranil-alquilo C₁₋₆; oxetanilo; u oxetanil-alquilo C₁₋₆; o R¹ y Rᵃ junto con los átomos, a los que están unidos, pueden formar un anillo de tres a seis eslabones que opcionalmente puede incluir un heteroátomo adicional elegido entre O, N y S, y que está sustituido por oxo, halógeno o alquilo C₁₋₆; R² es: halógeno; alcoxi C₁₋₆; ciano; alquinilo C₂₋₆; alquenilo C₂₋₆; haloalquilo C₁₋₆; halo-alcoxi C₁₋₆; cicloalquilo C₃₋₆, cuya porción cicloalquilo C₃₋₆ está opcionalmente sustituida por alquilo C₁₋₆; (cicloalquil C₃₋₆)-alquilo C₁₋₆, cuya porción cicloalquilo C₃₋₆ está opcionalmente sustituida por alquilo C₁₋₆; tetrahidrofuranilo; tetrahidrofuranil-alquilo C₁₋₆; acetilo; oxetanilo; u oxetanil-alquilo C₁₋₆; R³ᵃ es: -OR⁴; halógeno; ciano; alquilo C₁₋₆; haloalquilo C₁₋₆; cicloalquilo C₃₋₆ opcionalmente sustituido por alquilo C₁₋₆; (cicloalquil C₃₋₆)-alquilo C₁₋₆, cuya porción cicloalquilo C₃₋₆ está opcionalmente sustituida por alquilo C₁₋₆; tetrahidrofuranilo; tetrahidrofuranil-alquilo C₁₋₆; oxetanilo; u oxetanil-alquilo C₁₋₆; R³ᵇ es: hidrógeno, o R³ᵃ y R³ᵇ junto con los átomos, a los que están unidos, pueden formar un anillo de cinco o seis eslabones, que incluye opcionalmente uno o dos heteroátomos, cada uno de ellos se elige con independencia entre O, N y S, dicho anillo está opcionalmente sustituido una o varias veces por R⁸; R⁴ es: hidrógeno; alquilo C₁₋₆; haloalquilo C₁₋₆; (alcoxi C₁₋₆)-alquilo C₁₋₆; cicloalquilo C₃₋₆ opcionalmente sustituido por alquilo C₁₋₆ o halógeno; (cicloalquil C₃₋₆)-alquilo C₁₋₆, cuya porción cicloalquilo C₃₋₆ está opcionalmente sustituida por alquilo C₁₋₆ o halógeno; tetrahidrofuranilo; tetrahidrofuranil-alquilo C₁₋₆; oxetanilo; u oxetanil-alquilo C₁₋₆; R⁵ es: hidrógeno; o alquilo C₁₋₆; R⁶ es: hidrógeno; alquilo C₁₋₆; (alcoxi C₁₋₆)-alquilo C₁₋₆; hidroxi-alquilo C₁₋₆; amino-alquilo C₁₋₆; cicloalquilo C₃₋₆; (cicloalquil C₃₋₆)-alquilo C₁₋₆; heteroarilo, heterociclilo; o heterociclil-alquilo C₁₋₆; dichos cicloalquilo C₃₋₆, (cicloalquil C₃₋₆)-alquilo C₁₋₆, heteroarilo, heterociclilo y heterociclil-alquilo C₁₋₆ pueden estar en cada caso opcionalmente sustituidos por uno, dos, tres o cuatro grupos elegidos con independencia entre: alquilo C₁₋₆; haloalquilo C₁₋₆; alcoxi C₁₋₆; halo-alcoxi C₁₋₆; hidroxi; hidroxi-alquilo C₁₋₆; halógeno; nitrilo; (alquil C₁₋₆)-carbonilo; (alquil C₁₋₆)-sulfonilo; cicloalquilo C₃₋₆; (cicloalquil C₃₋₆)-alquilo C₁₋₆; (cicloalquil C₃₋₆)-carbonilo; amino; y heterociclilo; o dos de los grupos junto con los átomos, a los que están unidos, pueden formar un anillo de cinco o seis eslabones; o R⁵ y R⁶ junto con el átomo de nitrógeno al que están unidos forman un anillo de tres a siete eslabones, que opcionalmente incluye un heteroátomo adicional elegido entre O, N y S(O)ₙ, y que está opcionalmente sustituido por uno, dos, tres o cuatro grupos elegidos con independencia entre: alquilo C₁₋₆; haloalquilo C₁₋₆; alcoxi C₁₋₆; halo-alcoxi C₁₋₆; hidroxi; (alcoxi C₁₋₆)-alquilo C₁₋₆; hidroxi-alquilo C₁₋₆; halógeno, nitrilo; (alquil C₁₋₆)-carbonilo; (alquil C₁₋₆)-sulfonilo; cicloalquilo C₃₋₆; (cicloalquil C₃₋₆)-alquilo C₁₋₆; (cicloalquil C₃₋₆)-carbonilo; amino; o heterociclilo; o dos de los grupos junto con los átomos, a los que están unidos, pueden formar un anillo de cinco o seis eslabones; y R⁷ es: halógeno; alquilo C₁₋₆; alcoxi C₁₋₆; haloalquilo C₁₋₆; o halo-alcoxi C₁₋₆; R⁸ es: halógeno; alquilo C₁₋₆; u oxo.The compounds are useful for the treatment of diseases associated with the LRRK2 receptor, for example Parkinson's disease. Claim 1: Compounds of the formula (1) or pharmaceutically acceptable salts thereof, wherein: m is a number from 0 to 3; X is: -NRᵃ-; -OR-; or -S (O) ʳ-, in which r is a number from 0 to 2 and Rᵃ is hydrogen or C₁₋₆ alkyl; R¹ is: C₁₋₆ alkyl; C₂₋₆ alkenyl; C₂₋₆ alkynyl; C₁₋₆ haloalkyl; (C₁₋₆ alkoxy) -C₁₋₆ alkyl; hydroxy-C₁₋₆ alkyl; amino C alkyl; (C₁₋₆ alkylsulfonyl) -C₁₋₆ alkyl; C₃₋₆ cycloalkyl optionally substituted by C₁₋₆ alkyl or halogen; (C₃₋₆ cycloalkyl) -C₁₋₆ alkyl, whose C cuya cycloalkyl portion is optionally substituted by C₁₋₆ alkyl; tetrahydropyranyl; tetrahydrofuranyl; tetrahydrofuranyl-C₁₋₆ alkyl; oxetanyl; or oxetanyl-C₁₋₆ alkyl; or R¹ and Rᵃ together with the atoms, to which they are attached, can form a ring of three to six links that may optionally include an additional heteroatom chosen from O, N and S, and which is substituted by oxo, halogen or C₁ alkyl ₋₆; R² is: halogen; C₁₋₆ alkoxy; cyano; C₂₋₆ alkynyl; C₂₋₆ alkenyl; C₁₋₆ haloalkyl; C₁₋₆ haloalkoxy; C₃₋₆ cycloalkyl, whose C ciclo cycloalkyl portion is optionally substituted by C₁₋₆ alkyl; (C₃₋₆ cycloalkyl) -C₁₋₆ alkyl, whose C cuya cycloalkyl portion is optionally substituted by C₁₋₆ alkyl; tetrahydrofuranyl; tetrahydrofuranyl-C₁₋₆ alkyl; acetyl; oxetanyl; or oxetanyl-C₁₋₆ alkyl; R³ᵃ is: -OR⁴; halogen; cyano; C₁₋₆ alkyl; C₁₋₆ haloalkyl; C₃₋₆ cycloalkyl optionally substituted by C₁₋₆ alkyl; (C₃₋₆ cycloalkyl) -C₁₋₆ alkyl, whose C cuya cycloalkyl portion is optionally substituted by C₁₋₆ alkyl; tetrahydrofuranyl; tetrahydrofuranyl-C₁₋₆ alkyl; oxetanyl; or oxetanyl-C₁₋₆ alkyl; R³ᵇ is: hydrogen, or R³ᵃ and R³ᵇ together with the atoms, to which they are attached, can form a ring of five or six links, which optionally includes one or two heteroatoms, each of which is independently chosen from O, N and S, said ring is optionally substituted once or several times by R⁸; R⁴ is: hydrogen; C₁₋₆ alkyl; C₁₋₆ haloalkyl; (C₁₋₆ alkoxy) -C₁₋₆ alkyl; C₃₋₆ cycloalkyl optionally substituted by C₁₋₆ alkyl or halogen; (C₃₋₆ cycloalkyl) -C₁₋₆ alkyl, whose C cuya cycloalkyl portion is optionally substituted by C₁₋₆ alkyl or halogen; tetrahydrofuranyl; tetrahydrofuranyl-C₁₋₆ alkyl; oxetanyl; or oxetanyl-C₁₋₆ alkyl; R⁵ is: hydrogen; or C₁₋₆ alkyl; R⁶ is: hydrogen; C₁₋₆ alkyl; (C₁₋₆ alkoxy) -C₁₋₆ alkyl; hydroxy-C₁₋₆ alkyl; amino C alkyl; C₃₋₆ cycloalkyl; (C₃₋₆ cycloalkyl) -C₁₋₆ alkyl; heteroaryl, heterocyclyl; or heterocyclyl-C₁₋₆ alkyl; said C₃₋₆ cycloalkyl, (C₃₋₆ cycloalkyl) -C₁₋₆ alkyl, heteroaryl, heterocyclyl and heterocyclyl-C alquilo alkyl may in each case be optionally substituted by one, two, three or four groups independently selected from: alkyl C₁₋₆; C₁₋₆ haloalkyl; C₁₋₆ alkoxy; C₁₋₆ haloalkoxy; hydroxy; hydroxy-C₁₋₆ alkyl; halogen; nitrile; (C₁₋₆ alkyl) -carbonyl; (C₁₋₆ alkyl) -sulfonyl; C₃₋₆ cycloalkyl; (C₃₋₆ cycloalkyl) -C₁₋₆ alkyl; (C₃₋₆ cycloalkyl) -carbonyl; Not me; and heterocyclyl; or two of the groups together with the atoms, to which they are attached, can form a ring of five or six links; or R⁵ and R⁶ together with the nitrogen atom to which they are attached form a ring of three to seven links, which optionally includes an additional heteroatom chosen from O, N and S (O) ₙ, and which is optionally substituted by one, two , three or four groups chosen independently from: C₁₋₆ alkyl; C₁₋₆ haloalkyl; C₁₋₆ alkoxy; C₁₋₆ haloalkoxy; hydroxy; (C₁₋₆ alkoxy) -C₁₋₆ alkyl; hydroxy-C₁₋₆ alkyl; halogen, nitrile; (C₁₋₆ alkyl) -carbonyl; (C₁₋₆ alkyl) -sulfonyl; C₃₋₆ cycloalkyl; (C₃₋₆ cycloalkyl) -C₁₋₆ alkyl; (C₃₋₆ cycloalkyl) -carbonyl; Not me; or heterocyclyl; or two of the groups together with the atoms, to which they are attached, can form a ring of five or six links; and R⁷ is: halogen; C₁₋₆ alkyl; C₁₋₆ alkoxy; C₁₋₆ haloalkyl; or halo-C₁₋₆ alkoxy; R⁸ is: halogen; C₁₋₆ alkyl; or oxo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161564760P | 2011-11-29 | 2011-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR089182A1 true AR089182A1 (en) | 2014-08-06 |
Family
ID=47257804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120104438A AR089182A1 (en) | 2011-11-29 | 2012-11-27 | AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF LRRK2 |
Country Status (14)
Country | Link |
---|---|
US (1) | US8809331B2 (en) |
EP (1) | EP2785699B1 (en) |
JP (1) | JP6104268B2 (en) |
KR (1) | KR102088072B1 (en) |
CN (2) | CN105801493B (en) |
AR (1) | AR089182A1 (en) |
BR (1) | BR112014012217B1 (en) |
CA (1) | CA2850593C (en) |
ES (1) | ES2644566T3 (en) |
HK (1) | HK1195309A1 (en) |
MX (1) | MX356644B (en) |
RU (1) | RU2661197C2 (en) |
TW (1) | TW201329051A (en) |
WO (1) | WO2013079494A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2797947C (en) * | 2010-06-04 | 2019-07-09 | Charles Baker-Glenn | Aminopyrimidine derivatives as lrrk2 modulators |
ES2653967T3 (en) * | 2010-11-10 | 2018-02-09 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as modulators of LRRK2 |
US20140228384A1 (en) * | 2011-11-29 | 2014-08-14 | Genentech, Inc. | Assays and biomarkers for lrrk2 |
US8791130B2 (en) * | 2011-11-29 | 2014-07-29 | Genentech, Inc. | Aminopyrimidine derivatives as LRRK2 modulators |
EP2785709B1 (en) * | 2011-11-29 | 2017-05-10 | Genentech, Inc. | Aminopyrimidine derivatives as lrrk2 modulators |
BR112014027117B1 (en) * | 2012-05-03 | 2022-09-06 | Genentech, Inc | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS, THEIR USES, AND COMPOSITION |
WO2017156493A1 (en) | 2016-03-11 | 2017-09-14 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
EP3082819B1 (en) | 2013-12-20 | 2020-06-17 | Signal Pharmaceuticals, LLC | Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith |
WO2015176010A1 (en) | 2014-05-15 | 2015-11-19 | The United States Of America, As Represented By The Secretary, Departmentof Health & Human Services | Treatment or prevention of an intestinal disease or disorder |
WO2016007540A2 (en) | 2014-07-10 | 2016-01-14 | The J. David Gladstone Institutes | Compositions and methods for treating dengue virus infection |
WO2017087905A1 (en) | 2015-11-20 | 2017-05-26 | Denali Therapeutics Inc. | Compound, compositions, and methods |
CR20180592A (en) | 2016-06-16 | 2019-03-05 | Denali Therapeutics Inc | PIRIMIDIN-2-ILAMINO-1H-PIRAZOLES AS INHIBITORS OF LRRK2 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS |
ES2940911T3 (en) * | 2016-06-27 | 2023-05-12 | Rigel Pharmaceuticals Inc | 2,4-diamino-pyrimidine compounds and their use as IRAK4 inhibitors |
PE20210157A1 (en) | 2017-11-21 | 2021-01-26 | Denali Therapeutics Inc | POLYMORPHES AND SOLID FORMS OF A PYRIMIDINYLAMINE-PIRAZOLE COMPOUND AND PRODUCTION METHODS |
JP7284172B2 (en) | 2017-12-20 | 2023-05-30 | デナリ セラピューティクス インコーポレイテッド | Method for preparing pyrimidinyl-4-aminopyrazole compounds |
KR102063155B1 (en) | 2018-04-11 | 2020-01-08 | 한국과학기술연구원 | multi-substituted pyrimidine derivatives showing excellent kinase inhibitory activities |
EP3866801A4 (en) * | 2018-10-16 | 2022-11-09 | Dana-Farber Cancer Institute, Inc. | Degraders of wild-type and mutant forms of lrrk2 |
CN111732548B (en) * | 2020-06-11 | 2022-06-17 | 浙江大学 | N2-carbamyl aromatic ring-2-aminopyrimidine derivatives and medical application thereof |
CN116685325A (en) | 2020-10-20 | 2023-09-01 | 豪夫迈·罗氏有限公司 | Combination therapy of a PD-1 axis binding antagonist and an LRRK2 inhibitor |
WO2022216097A1 (en) * | 2021-04-08 | 2022-10-13 | 주식회사 스탠다임 | Novel lrrk2 inhibitor |
WO2024073073A2 (en) * | 2022-09-30 | 2024-04-04 | Neuron23, Inc. | Kinase modulators and methods of use thereof |
WO2024097394A1 (en) | 2022-11-03 | 2024-05-10 | Denali Therapeutics Inc. | Solid and co-crystal forms of a pyrimidine triazole compound |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE407678T1 (en) * | 2001-10-17 | 2008-09-15 | Boehringer Ingelheim Pharma | PYRIMIDINE DERIVATIVES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS, THEIR USE AND METHOD FOR THEIR PRODUCTION |
JP2006508997A (en) * | 2002-11-28 | 2006-03-16 | シエーリング アクチエンゲゼルシャフト | Chk-, Pdk- and Akt-inhibiting pyrimidines, their preparation and use as pharmaceuticals |
RU2356901C2 (en) * | 2003-07-30 | 2009-05-27 | Райджел Фармасьютикалз, Инк. | 2,4-pyrimidindiamine compounds having effect in case of autoimmune disorders |
WO2007149789A2 (en) | 2006-06-22 | 2007-12-27 | Applera Corporation | Conversion of target specific amplification to universal sequencing |
DE102007010801A1 (en) * | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Use of new and known 2,4-diaminopyrimidine derivatives as fungicides, especially for controlling phytopathogenic fungi |
WO2009127642A2 (en) * | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
TW201024281A (en) * | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
WO2010129053A2 (en) * | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
MX339811B (en) * | 2009-09-16 | 2016-06-08 | Celgene Avilomics Res Inc * | Protein kinase conjugates and inhibitors. |
ES2512727T3 (en) | 2009-09-29 | 2014-10-24 | Glaxo Group Limited | New compounds |
CA2797947C (en) * | 2010-06-04 | 2019-07-09 | Charles Baker-Glenn | Aminopyrimidine derivatives as lrrk2 modulators |
ES2653967T3 (en) | 2010-11-10 | 2018-02-09 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as modulators of LRRK2 |
EP2785709B1 (en) * | 2011-11-29 | 2017-05-10 | Genentech, Inc. | Aminopyrimidine derivatives as lrrk2 modulators |
US8791130B2 (en) * | 2011-11-29 | 2014-07-29 | Genentech, Inc. | Aminopyrimidine derivatives as LRRK2 modulators |
CA2852609C (en) * | 2011-11-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as lrrk2 modulators |
CN104093426B (en) * | 2011-11-30 | 2019-06-28 | 健泰科生物技术公司 | The radioligand that the Value linear and carbon -11 that positron emission tomography (PET) for LRRK2 is imaged mark |
-
2012
- 2012-11-27 AR ARP120104438A patent/AR089182A1/en not_active Application Discontinuation
- 2012-11-28 KR KR1020147017825A patent/KR102088072B1/en active IP Right Grant
- 2012-11-28 TW TW101144559A patent/TW201329051A/en unknown
- 2012-11-28 CA CA2850593A patent/CA2850593C/en active Active
- 2012-11-28 CN CN201610165356.XA patent/CN105801493B/en active Active
- 2012-11-28 EP EP12791761.5A patent/EP2785699B1/en active Active
- 2012-11-28 JP JP2014543866A patent/JP6104268B2/en active Active
- 2012-11-28 RU RU2014124950A patent/RU2661197C2/en active
- 2012-11-28 CN CN201280058444.XA patent/CN103987698B/en active Active
- 2012-11-28 ES ES12791761.5T patent/ES2644566T3/en active Active
- 2012-11-28 WO PCT/EP2012/073762 patent/WO2013079494A1/en active Application Filing
- 2012-11-28 MX MX2014006027A patent/MX356644B/en active IP Right Grant
- 2012-11-28 US US13/687,437 patent/US8809331B2/en active Active
- 2012-11-28 BR BR112014012217-2A patent/BR112014012217B1/en active IP Right Grant
-
2014
- 2014-08-28 HK HK14108772.1A patent/HK1195309A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN105801493B (en) | 2018-09-21 |
CN103987698A (en) | 2014-08-13 |
BR112014012217A2 (en) | 2017-05-30 |
KR102088072B1 (en) | 2020-03-11 |
CN105801493A (en) | 2016-07-27 |
RU2014124950A (en) | 2016-01-27 |
JP6104268B2 (en) | 2017-03-29 |
WO2013079494A1 (en) | 2013-06-06 |
HK1195309A1 (en) | 2014-11-07 |
TW201329051A (en) | 2013-07-16 |
CA2850593C (en) | 2020-03-10 |
US8809331B2 (en) | 2014-08-19 |
CN103987698B (en) | 2016-04-20 |
BR112014012217B1 (en) | 2022-06-21 |
EP2785699A1 (en) | 2014-10-08 |
CA2850593A1 (en) | 2013-06-06 |
MX2014006027A (en) | 2014-06-04 |
US20130157999A1 (en) | 2013-06-20 |
ES2644566T3 (en) | 2017-11-29 |
EP2785699B1 (en) | 2017-09-06 |
JP2015501810A (en) | 2015-01-19 |
MX356644B (en) | 2018-06-07 |
RU2661197C2 (en) | 2018-07-13 |
KR20140097496A (en) | 2014-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR089182A1 (en) | AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF LRRK2 | |
AR081577A1 (en) | AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF THE LRRK2 | |
AR127309A2 (en) | PYRDAZINONE DERIVATIVES | |
AR062696A1 (en) | N- (1-HETARIL- PIPERIDIN -4-IL) - (HET) ARILAMIDS AS MODULATORS OF THE EP2 RECEIVER. | |
AR090760A1 (en) | BENZOTIAZOL COMPOUNDS AND THEIR USE AGAINST HIV VIRUS | |
AR078408A1 (en) | DERIVATIVES OF INDOL AS MODULATORS OF THE CRAC | |
AR089774A1 (en) | DERIVATIVES OF INDOLIZINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
ECSP13012611A (en) | PIRAZOL-AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF THE LRRK2 | |
PE20190446A1 (en) | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLIN RECEPTOR M4 | |
CR20120361A (en) | UNITED DIVALENT AND HETEROCYCLIC COMPOUNDS BY OXA BRIDGE RELATED TO NICOTINE AND SAME PREPARATION METHODS | |
AR077328A1 (en) | DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | |
PE20161251A1 (en) | FUSIONED BICYCLIC HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | |
AR100806A1 (en) | 3-QUINASA PHOSFATIDYLINOSITOL INHIBITORS | |
CO6852096A2 (en) | Pesticide methods that use substituted 3-pyridyl thiazole compounds and derivatives to combat animal pests | |
AR077292A1 (en) | DERIVATIVES OF PIPERAZIN - QUINOLIN SULFONAMIDS AND PHARMACEUTICAL COMPOSITIONS | |
AR100808A1 (en) | 3-QUINASA PHOSFATIDYLINOSITOL INHIBITORS | |
AR082111A1 (en) | FUROPIRIDINES OR CONDENSED TENOPIRIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM USEFUL TO TREAT PSYCHOTIC AND CENTRAL NERVOUS SYSTEM DISORDERS, AND THE SAME PREPARATION METHOD | |
AR088829A1 (en) | CYCLHEXYLAMINE DERIVATIVES THAT HAVE ACTIVITY AS ADRENERGIC B2 AGONISTS AND AS M3 MUSCARINIC ANTAGONISTS | |
AR072803A1 (en) | TETRAHYDROCINOLINS AS INHIBITORS OF THE 11- BETA -HSD1 FOR DIABETES | |
AR100810A1 (en) | 3-QUINASA PHOSFATIDYLINOSITOL INHIBITORS | |
AR088828A1 (en) | CYCLHEXYLAMINE DERIVATIVES THAT HAVE ACTIVITY AS ADRENERGIC B2 AGONISTS AND AS M3 MUSCARINIC ANTAGONISTS | |
AR090557A1 (en) | ADIDENIC AGONIST IMIDAZOLIC DERIVATIVES a2 | |
AR072622A1 (en) | IMIDAZO DERIVATIVES [2,1-B] [1,3,4] TIADIAZOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF THEM FOR THE TREATMENT OF TUMORS AND OTHER DISEASES INDICATED BY KINASES | |
CU20090048A7 (en) | NEW DERIVATIVES OF DIOSMETINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
EA201591815A1 (en) | BICYCLO [2.2.2] ACIDS - GPR120 MODULATORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |